Cargando…
Development of a glycoproteomic strategy to detect more aggressive prostate cancer using lectin-immunoassays for serum fucosylated PSA
BACKGROUND: Prostate-specific antigen (PSA) is commonly used as a serum biomarker for the detection of prostate cancer. However, levels of PSA in serum do not reliably distinguish aggressive prostate cancer from non-aggressive disease. Therefore, there is an urgent need for biomarkers that can diffe...
Autores principales: | Wang, Ce, Höti, Naseruddin, Lih, Tung-Shing Mamie, Sokoll, Lori J., Zhang, Rui, Zhang, Zhen, Zhang, Hui, Chan, Daniel W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6451306/ https://www.ncbi.nlm.nih.gov/pubmed/30996714 http://dx.doi.org/10.1186/s12014-019-9234-4 |
Ejemplares similares
-
Urinary PSA and Serum PSA for Aggressive Prostate Cancer Detection
por: Höti, Naseruddin, et al.
Publicado: (2023) -
Urinary glycoproteins associated with aggressive prostate cancer
por: Dong, Mingming, et al.
Publicado: (2020) -
Serum Fucosylated Prostate-specific Antigen (PSA) Improves the Differentiation of Aggressive from Non-aggressive Prostate Cancers
por: Li, Qing Kay, et al.
Publicado: (2015) -
Proteomic characterization of primary and metastatic prostate cancer reveals reduced proteinase activity in aggressive tumors
por: Li, Qing Kay, et al.
Publicado: (2021) -
Urinary marker panels for aggressive prostate cancer detection
por: Lih, Tung-Shing Mamie, et al.
Publicado: (2022)